MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, TPST had -$5,902K decrease in cash & cash equivalents over the period. -$7,598K in free cash flow.

Cash Flow Overview

Change in Cash
-$5,902K
Free Cash flow
-$7,598K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Acquired in-process research and...
    • Proceeds from issuance of common...
    • Proceeds from issuance of common...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accounts payable
    • Operating lease liabilities
    • Prepaid expenses and other asset...

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-27,696 -4,021 -3,511 -18,730
Depreciation expense
60 65 66 135
Stock-based compensation expense
226 576 61 2,481
Non-cash lease expense
292 285 279 539
Non-cash interest and other expense, net
0 8 1 76
Acquired in-process research and development
19,927 ---
Prepaid expenses and other assets
71 -33 -243 -339
Accounts payable
-454 116 -3,794 2,266
Accrued expenses and other liabilities
405 -372 134 -3,166
Interest payable
0 0 0 -59
Operating lease liabilities
-287 -264 -258 -348
Cash used in operating activities
-7,598 -3,574 -6,779 -16,467
Purchase of property and equipment
0 0 0 0
Cash used in investing activities
0 0 0 0
Proceeds from the issuance of common stock, net of issuance costs
-1,032 0 5,013
Proceeds from the issuance of pre-funded warrants, net of issuance costs
-1,451 0 1,858
Proceeds from issuance of common stock, pre-funded warrants and common stock warrants, net of issuance costs
1,272 ---
Proceeds from the issuance of common stock warrants, net of issuance costs
-1,284 --
Proceeds from issuance of common stock and common stock warrants to related party net of issuance costs
424 ---
Repayment of loan
0 0 0 6,426
Proceeds from the issuance of common stock under equity plan awards
0 0 13 34
Cash provided by (used in) financing activities
1,696 3,767 13 479
Net decrease in cash, cash equivalents and restricted cash
-5,902 193 -6,766 -15,988
Cash, cash equivalents and restricted cash at beginning of period
8,150 7,957 30,711 -
Cash, cash equivalents and restricted cash at end of period
2,248 8,150 7,957 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock,...$1,272K Proceeds from issuance ofcommon stock and common...$424K Cash provided by(used in) financing...$1,696K Net decrease incash, cash...-$5,902K Canceled cashflow$1,696K Acquired in-processresearch and development$19,927K Accrued expenses andother liabilities$405K Non-cash lease expense$292K Stock-based compensationexpense$226K Depreciation expense$60K Cash used inoperating activities-$7,598K Canceled cashflow$20,910K Net loss-$27,696K Accounts payable-$454K Operating leaseliabilities-$287K Prepaid expenses andother assets$71K

Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics, Inc. (TPST)